Andrew Obenshain Sells 21,805 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock
Andrew Obenshain Sells 21,805 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $4.39, for a total transaction of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a legal filing with the SEC, which is available through this link.
蓝鸟生物公司(Bluebird Bio,Inc.)首席执行官安德鲁·奥本斯坦在日期为8月4日(星期四)的交易中出售了21,805股该公司股票。该股以4.39美元的平均价格出售,总成交金额为95723.95美元。交易完成后,首席执行官现在拥有该公司247,131股,价值约1,084,905.09美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过这个链接获得。
bluebird bio Stock Up 13.4 %
蓝鸟生物股票上涨13.4%
BLUE traded up $0.75 during trading on Monday, hitting $6.34. The company's stock had a trading volume of 10,617,046 shares, compared to its average volume of 4,637,974. The business's 50 day simple moving average is $4.22 and its 200-day simple moving average is $4.76. The firm has a market cap of $453.02 million, a PE ratio of -0.74 and a beta of 1.29. bluebird bio, Inc. has a one year low of $2.87 and a one year high of $25.39.
在周一的交易中,Blue的交易价格上涨了0.75美元,达到6.34美元。该公司股票的成交量为10,617,046股,而其平均成交量为4,637,974股。该业务的50日简单移动均线切入位为4.22美元,200日简单移动均线切入位为4.76美元。该公司市值为4.5302亿美元,市盈率为-0.74,贝塔系数为1.29。蓝鸟生物公司的一年低点为2.87美元,一年高位为25.39美元。
bluebird bio (NASDAQ:BLUE – Get Rating) last announced its earnings results on Monday, May 9th. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.40). bluebird bio had a negative return on equity of 130.19% and a negative net margin of 2,141.34%. The company had revenue of $1.95 million during the quarter, compared to the consensus estimate of $0.17 million. During the same period in the prior year, the business posted ($3.07) earnings per share. bluebird bio's revenue for the quarter was up 117.6% compared to the same quarter last year. Equities research analysts expect that bluebird bio, Inc. will post -5.07 EPS for the current fiscal year.
青鸟生物(纳斯达克:Blue-Get Rating)最近一次公布财报是在5月9日(星期一)。这家生物技术公司公布的季度每股收益为1.66美元,低于分析师普遍预期的1.26美元和0.40美元。蓝鸟生物的净资产回报率为负130.19%,净利润率为负2,141.34%。该公司本季度营收为195万美元,而市场普遍预期为17万美元。去年同期,该业务公布的每股收益为3.07美元。蓝鸟生物本季度的收入与去年同期相比增长了117.6。股票研究分析师预计,蓝鸟生物公司本财年每股收益将达到5.07欧元。
Hedge Funds Weigh In On bluebird bio
对冲基金对蓝鸟生物的看法
Analyst Ratings Changes
分析师评级发生变化
Several research analysts have recently issued reports on the stock. Raymond James upgraded shares of bluebird bio from a "market perform" rating to an "outperform" rating and set a $8.00 target price on the stock in a research note on Tuesday, August 2nd. Wedbush cut their target price on bluebird bio from $10.00 to $8.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 10th. Morgan Stanley reduced their target price on bluebird bio to $3.00 and set an "underweight" rating for the company in a report on Tuesday, May 17th. Finally, Barclays raised bluebird bio from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $3.00 to $5.00 in a research report on Friday. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $11.86.
几位研究分析师最近发布了关于该股的报告。8月2日,雷蒙德·詹姆斯在一份研究报告中将蓝鸟生物公司的股票评级从市场表现上调至跑赢大盘,并为该公司股票设定了8.00美元的目标价。5月10日,周二,韦德布什在一份研究报告中将蓝鸟生物的目标价从10.00美元下调至8.00美元,并将该股的评级定为中性。摩根士丹利在5月17日周二的一份报告中将蓝鸟生物的目标价下调至3.00美元,并将该公司的评级定为“减持”。最后,在上周五的一份研究报告中,巴克莱将蓝鸟生物的评级从减持上调至同等权重,并将该公司的目标价从3.00美元上调至5.00美元。两名分析师对该股的评级为卖出,12名分析师发布了持有评级,两名分析师发布了买入评级,一名分析师对该公司股票给予了强烈的买入评级。根据MarketBeat.com的数据,该公司目前的普遍评级为持有,平均目标价为11.86美元。
About bluebird bio
关于蓝鸟传记
(Get Rating)
(获取评级)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
蓝鸟生物公司是一家生物技术公司,研究、开发和商业化针对严重遗传病的变革性基因疗法。其用于治疗严重遗传性疾病的候选产品包括用于治疗输血依赖型β-地中海贫血的贝替贝吉基因Autotemcel;用于治疗镰状细胞病(SCD)的lovotieglogene autemcel;以及用于治疗大脑肾上腺脑白质营养不良的伊利伐多烯Autotemcel。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- How to Use the MarketBeat Dividend Calculator
- Two Appealing Biotech Stocks for Two Distinct investors
- Is Tyson Foods A Buy On Post-Earnings Weakness?
- Is DoorDash Ready To Sprint Higher?
- Electric Vehicles Can Drive Alcoa Stock Higher
- 免费获取StockNews.com关于蓝鸟生物的研究报告(蓝色)
- 如何使用MarketBeat分红计算器
- 两只对两个不同投资者有吸引力的生物技术股票
- 泰森食品是在盈利疲软的基础上买入的吗?
- DoorDash准备好冲刺更高了吗?
- 电动汽车可以推动美国铝业股价走高
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
获得蓝鸟生物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对蓝鸟生物和相关公司的最新新闻和分析师评级的每日简明摘要。